ELSEVIER Prostaglandins & other Lipid Mediators 70 (2003) 363–364

PROSTAGLANDINS & other LIPID MEDIATORS

Author Index

Acosta, T.J., 339
Akmal, Y., 61, 303, 317
Allorge, D., 31
Althouse, G.C., 285
Ang, J.G., 61
Asrat, T., 303
Attenello, F., 317

Ballou, L.R., 161
Barletta, E., 209
Bartoov, B., 291
Beharry, K., 61, 303, 317
Berisha, B., 339
Bharathi, D., 259
Bridges, P.J., 195
Broly, F., 31
Buluç, M., 227

Campbell, W.B., 39
Cao, Y.-Z., 131
Carlson, J.C., 145
Carroll, M., 257
Cauffiez, C., 31
Chana Reddy, C., 131
Cheng, H., 285
Chevalier, D., 31
Ching, L., 195

Dworski, R., 185

Eley, K., 257

Fallani, A., 209
Fields, M.J., 119
Flannery, P.J., 79
Fuchs, A.-R., 119

Giorgi, G., 209
Graddy, L.G., 119
Grenett, H.E., 91
Grieco, B., 209
Gürdal, H., 227

Hagaman, D., 185
Hase, M., 107
Hausman, N., 303
Hayashi, K., 339
Hayes, J.D., 267
Hsu, W.H., 285
Hughes, M.J., 39
Humphrey, J., 1

Jeong, S.-W., 169
Jiang, L.-j., 331
Jowsey, I.R., 267

Kalyankrishna, S., 13
Kankofer, M., 51
Kenani, A., 31
Kikuta, Y., 361
Kim, H.-S., 169
Kim, I.-K., 169
Kim, J.W., 169
Kobayashi, S.-i., 339
Kotwica, J., 351
Kowalski, A.A., 119
Ku, D.D., 91
Kusunose, E., 361
Kusunose, M., 361

Laulederkind, S.J.F., 161
LeaMaster, B.R., 195
Lepetit, C., 31
Lhermitte, M., 31
Lo-Guidice, J.-M., 31
Lyons, C., 317

Malik, K.U., 13
Marcus, S., 291
Melli, M., 227
Miao, Y.-g., 259, 331
Migot-Nabias, F., 31
Miyamoto, A., 339
Mlynarczuk, J., 351
Modanlou, H.D., 61
Moore, G.B.T., 267
Mugnai, G., 209
Mullan, M., 1
Murdock, P.R., 267
Murphy, G.J., 267
Murray, J., 185

Nageotte, M.P., 317
Narayansingh, R.M., 145
Nishihara, K., 303
Nishihara, K.C., 61

Oates, J., 185
Obregon, D.F., 1
Ohtani, M., 339
Ozaki, N., 61

Paris, D., 1
Parmentier, J.-H., 13
Pfister, S.L., 39

Raghow, R., 161
Rekawiecki, R., 351
Rhim, H., 169
Rosolowsky, M., 39
Ruggieri, S., 209

Salvini, L., 209
Sasser, R.G., 195
Schams, D., 339
Senchyna, M., 145
Sheller, J., 185
Shemesh, M., 291
Shore, L., 291
Skarzynski, D., 351
Smith, S.A., 267
Sordillo, L.M., 131
Spurney, R.F., 79

PII: S0090-6980(02)00159-4

Stamford, I., 257

Tanaka, M., 107
Tavares, I., 257
Townsend, K.P., 1

Urthaler, F., 91

Vincent, D.L., 195

Wall, B.M., 161
Weaver, J.A., 131
Weems, C.W., 195
Weems, Y.S., 195
Wolkowicz, P.E., 91
Wong, P., 257

Yamada, Y., 107
Yehuda, R., 291
Yokota, M., 107

ELSEVIER Prostaglandins & other Lipid Mediators 70 (2003) 365–366

PROSTAGLANDINS & other LIPID MEDIATORS

Subject Index

Adipose tissue, 267
Air pouch, 227
Allergen challenge, 185
Alzheimer's disease, 1
Antioxidants, 131
Apolipoprotein E-deficient, 107
Apoptosis, 13, 169
Arachidonic acid, 13
Artificial insemination, 285
Asthma, 185
Atherosclerosis, 107

Boar semen, 285
Bombyx mori L, 259, 331
Bovine, 351
Brain slices, 1
Bronchoalveolar lavage, 185
Bull, 291

Caspase activities, 169
Celecoxib, 61
Cervical mucosa, 119
Cervix, 317
CL, 339
Corpus luteum, 145, 351
Cow, 119, 339
Cryptorchid, 291
Cyclooxygenase, 1
Cyclooxygenase-2, 227
Cytokines, 209

Desensitization, 79
Dexamethasone, 61

Eicosanoid, 79
Eicosanoids, 131
Ejaculate, 285
Endothelial cells, 39
Eosinophils, 185
EP1, 91
EP receptor, 317
Ethnic group, 31
Ewes, 195

Fetal, 303
5′-Flanking region polymorphism, 31

G protein-coupled receptor kinase, 79
Gas chromatography–mass spectrometry/negative ion chemical ionization, 209
Gonads, 259
Gono-somatic index (GSI), 259

Histamine, 39
HL-60 cells, 169
Hydroxynonenal, 13
Hyperoxia, 61
Hypoplasia, 161

IL-5, 185
Immunity, 131
Inflammation, 1
8-iso-prostaglandin $F_{2\alpha}$, 51

Kidney, 161

Lactate dehydrogenase (LDH) activity, 259
Left atria, 91
Lipids, 331
Lipoproteins, 351
Luteolysis, 339

Malondialdehyde, 13
MDS, 339
Metastasis, 209
Microvessels, 1
Mid-gut, 331
Mifepristone, 195
Misoprostol, 185, 227, 317
Murine, 161
Myometrium, 317

Nuclear receptor, 267

OT, 119
Oxidation products, 13
Oxidative damage, 51
Oxidative stress, 131

p38 MAPK, 1
PAF, 209
Perfusion, 303
PGE_1, 119
PGE_2, 119, 351
$PGF_{2\alpha}$, 285
Phospholipase D activation, 131
Platelet-activating factor acetylhydrolase, 107
Platelets, 39
Pregnancy, 195
Progesterone, 351
Prostacyclin, 39
Prostacyclin synthase (CYP8A1), 31
Prostaglandin, 1, 267, 339
Prostaglandin E_2, 227, 317
Prostaglandin $F_{2\alpha}$, 145
Prostaglandin $F_{2\alpha}$ ($PGF_{2\alpha}$), 259, 331
Prostaglandin H synthase-2, 161
Prostaglandin $PGF_{2\alpha}$, 195
Prostaglandin synthase-2, 145
Prostanoids, 61

Ram, 291
Rat, 131, 145
Regression, 145
Retained placenta, 51

PII: S0090-6980(02)00160-0

Rho A-activated protein kinases, 91

12(S)-HPETE, 13
15(S)-HPETE, 13
Seminal plasma, 291
Silk gland, 331
Silkworm, 259, 331

Thromboxane, 39, 79
Thromboxane B_2, 227
Tumor cell lines, 209

Uteroplacental, 303

Variable number of tandem repeats (VNTRs), 31
Vascular smooth muscle cell, 13